- Home
- BPRN vs YMAB Comparison
BPRN vs YMAB Comparison
Compare BPRN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPRN
- YMAB
- Stock Information
- Founded
- BPRN 2007
- YMAB 2015
- Country
- BPRN United States
- YMAB United States
- Employees
- BPRN N/A
- YMAB N/A
- Industry
- BPRN Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BPRN Finance
- YMAB Health Care
- Exchange
- BPRN Nasdaq
- YMAB Nasdaq
- Market Cap
- BPRN 216.1M
- YMAB 192.4M
- IPO Year
- BPRN N/A
- YMAB 2018
- Fundamental
- Price
- BPRN $31.91
- YMAB $8.51
- Analyst Decision
- BPRN Strong Buy
- YMAB Buy
- Analyst Count
- BPRN 1
- YMAB 11
- Target Price
- BPRN $35.00
- YMAB $15.02
- AVG Volume (30 Days)
- BPRN 9.6K
- YMAB 1.5M
- Earning Date
- BPRN 07-24-2025
- YMAB 08-08-2025
- Dividend Yield
- BPRN 3.75%
- YMAB N/A
- EPS Growth
- BPRN N/A
- YMAB N/A
- EPS
- BPRN 1.00
- YMAB N/A
- Revenue
- BPRN $68,942,000.00
- YMAB $85,385,000.00
- Revenue This Year
- BPRN $14.19
- YMAB N/A
- Revenue Next Year
- BPRN $15.48
- YMAB $15.23
- P/E Ratio
- BPRN $32.01
- YMAB N/A
- Revenue Growth
- BPRN N/A
- YMAB N/A
- 52 Week Low
- BPRN $27.25
- YMAB $3.55
- 52 Week High
- BPRN $39.35
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- BPRN 55.72
- YMAB 81.64
- Support Level
- BPRN $29.81
- YMAB $4.16
- Resistance Level
- BPRN $32.80
- YMAB $8.54
- Average True Range (ATR)
- BPRN 1.16
- YMAB 0.24
- MACD
- BPRN -0.00
- YMAB 0.47
- Stochastic Oscillator
- BPRN 68.65
- YMAB 99.32
About BPRN Princeton Bancorp Inc. (PA)
Princeton Bancorp Inc is a banking company. It is a full-service financial institution that provides business and personal banking. Its personal banking and business banking services include checking accounts and savings accounts. It offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loans, and consumer loans, including home equity loans and lines of credit. The Bank also has two retail branches and conducts loan origination activities in select areas of the New York City metropolitan area.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.